THÉA INTRODUCES IVIZIA OTC EYECARE PRODUCTS IN THE UNITED STATES

Théa Pharma Inc. has announced iVizia’s line of over-the-counter eyecare products is now available in the United States. The line includes lubricating eye drops, lubricating eye gel, and three daily hygiene options for sensitive eyelids.

According to Théa, iVizia eye drops are free of preservatives and offer extended relief and ocular surface protection to patients with any type of dry eye, including those who wear contact lenses. Théa shares that clinical studies have shown the formula’s combination of trehalose and hyaluronic acid increases tear thickness, improves scores on the Ocular Surface Disease Index, decreases ocular surface inflammation, and relieves symptoms like blurred vision, stinging, and itching.

The three lid hygiene formulas—iVIZIA Eyelid Cleansing Wipes, iVIZIA Micellar Eyelid Cleanser, and iVIZIA Eyelid Cleansing Gel—gently remove oils and makeup from dry, irritated, sensitive eyelids, shares Théa. Visit theapharmainc.com .

JOHNSON & JOHNSON VISION UPDATES TEARSCIENCE ACTIVATOR CLEAR

Johnson & Johnson Vision has announced the next generation of TearScience Activator Clear, used to deliver treatment for meibomian gland dysfunction (MGD) with the TearScience LipiFlow Thermal Pulsation System.

The updated TearScience Activator Clear features a single-piece eye cup and translucent design that, according to the company, allows for more efficient and accurate positioning in the eye, thereby enabling delivery of heat and pressure evenly across the entire lid.

Additionally, the updated manufacturing process now uses fewer raw materials than its predecessor, shares Johnson & Johnson Vision.

TearScience Activator Clear is available as treatment for MGD with the TearScience LipiFlow treatment system in the United States, Canada, Hong Kong, Chile, and Argentina; it will continue to roll out to more countries throughout 2022. Visit jjvision.com 

SANTEN’S VERKAZIA AVAILABLE TO TREAT VKC

Santen Inc. has released Verkazia in the United States to treat vernal keratoconjunctivitis (VKC). The first and only FDA-approved topical immunomodulator for treating VKC in children and adults, Verkazia is administered as an eye drop.

According to Santen, Verkazia is a prescription-only cationic nanoemulsion that provides improved ocular bioavailability of cyclosporine, which has been shown to be effective in managing VKC. The eye drops reportedly work by blocking the release of pro-inflammatory cytokines, such as IL-2, that can cause the chronic allergic inflammation of the ocular surface seen in patients who are affected by VKC.

Verkazia is available in the U.S., Canada, and select countries across Asia and Europe. Visit santen.com .